That work is now being recognized in several ways. Dr. Roy Smith recently received the 2025 Presidential Award from the American Porphyria Foundation (APF), one of the field’s highest honors, and will be featured in the upcoming Netflix documentary It’s All in Your Head, which explores the long and often frustrating path many patients face before receiving an accurate diagnosis.
At the same time, Yvette Yien, PhD, associate professor of medicine and member of the Center for Iron and Hematology Disorders (CIHD), was awarded the 2025 International Human Heme Biosynthesis and Porphyrias Research Prize for her contributions to heme biology research.
Together, these honors point to the strength of Pitt and UPMC’s work in rare hematologic disorders—not as isolated achievements, but as part of a larger, deeply connected effort.
Porphyria refers to a group of conditions caused by disruptions in the body’s heme pathway, the multi-step process required to produce heme, an essential component of hemoglobin and many other cellular systems. When that process breaks down, toxic intermediates can build up, leading to a wide range of symptoms, from severe abdominal pain and neurologic issues to blistering skin disease and extreme sensitivity to sunlight.
Because these symptoms often overlap with more common conditions, diagnosis is often delayed. “The biggest challenge in reaching the diagnosis, bar none, is wondering whether the patient may have the disease in the first place,” Smith said. On average, he noted, patients may wait 15 to 17 years before receiving an accurate diagnosis.
That challenge is at the heart of It’s All in Your Head, which highlights how patients are frequently told their symptoms are psychological rather than physiological. “This insightful and dramatic documentary records the experiences of patients with a variety of porphyrias and their interactions with the medical community,” describes Smith. “Many, if not all, were consistently ignored or mishandled during the early phases of their diseases leading to delays in diagnosis and the introduction of appropriate treatment – sometimes with devastating consequences.” Smith hopes the film will encourage clinicians to keep porphyria in mind when faced with complex or unexplained cases to recognize just how varied the disease can be.
Over the course of Smith’s career, the field has changed dramatically. What was once understood mainly through clinical observation is now defined at the molecular level, with researchers identifying the specific enzyme defects and genetic mutations behind each form of porphyria. Advances in biochemical testing and genetic analysis have made diagnosis more precise and, in turn, care more targeted.
New therapies are also emerging from that deeper understanding. Some treatments use small interfering RNA to interrupt early steps in heme synthesis and prevent the buildup of toxic compounds, while others in development aim to block harmful precursor transport or protect vulnerable tissues.
At Pitt, these clinical advances are closely tied to ongoing basic science research. Investigators across the Division of Classical Hematology and the Vascular Medicine Institute are studying the fundamentals of heme production, iron metabolism, and red blood cell development—work that not only informs porphyria care but also broadens understanding of hematologic disease more generally.
Dr. Yvette Yien’s research is central to that effort. Her lab focuses on how iron metabolism and heme regulation shape cellular development, using red blood cells as a model to better understand how these systems function—and what happens when they don’t.
“Understanding the basic physiology of how iron and heme are regulated allows us to understand the biological basis of disease and therapeutic mechanisms,” Yien said.
Her work also highlights how basic discovery can translate into real patient impact. As a postdoctoral researcher, Yien helped identify a mutation in a mitochondrial protein, CLPX, as a cause of porphyria. That discovery led clinicians to try a targeted intervention—iron supplementation—which significantly improved a patient’s symptoms, including severe photosensitivity that had limited daily life.
“This was tremendously gratifying,” she said. “not only because it helped this specific patient, but also realizing that such a simple intervention as knowing how to handle the patient’s iron status could have a profound effect on a disease and a person’s quality of life.”
This kind of bench-to-bedside connection is a defining feature of Pitt’s approach. Yien and her colleagues are also exploring how iron metabolism contributes to other hematologic conditions, including sickle cell disease, and investigating how biological differences, such as sex-specific responses to physiologic stress, may inform more personalized therapies in the future.
Rare diseases like porphyria play an important role in advancing this kind of discovery. “Studying the genetic basis of rare diseases has historically shed a lot of light on the physiological function of the genes involved,” Yien said. “The basic science studies that follow up on the disease itself have often led to understanding the basic physiology behind the process which have much broader implications – often applicable to treating more common diseases, as well.”
That progress is made possible, in part, by the academic medical center environment at Pitt, where clinicians and scientists work closely together. Shared spaces, seminar series, and cross-disciplinary partnerships help ideas move more quickly from the lab to clinical application.
Smith emphasized that this collaborative model is essential for managing complex conditions like porphyria, which often require input from multiple specialties. UPMC provides coordinated access to experts in neurology, gastroenterology, dermatology, hematology, genetic counseling, and transplantation—resources that are rarely available in a single setting.
The Division of Classical Hematology’s dedicated focus on rare hematologic disorders further strengthens this effort, ensuring that patients receive the time, attention, and specialized knowledge these conditions demand, while also creating a platform for clinical research and innovation.
As porphyria gains wider public visibility, Pitt and UPMC are helping ensure that awareness is matched by expertise. The recognition of Smith and Yien, along with the release of It’s All in Your Head, highlights a program that is not only advancing knowledge, but also reshaping how rare diseases are understood, diagnosed, and treated.
At its core, that work reflects a broader mission: to bring together science, clinical care, and collaboration in ways that improve outcomes for patients who too often go unseen—and to continue pushing the boundaries of discovery in even the rarest of diseases.